Quick Links

Contact Us

Rationale and design of the EMBRACE STEMI study: a phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the

Authors: Anjan K Chakrabarti|||Kristin Feeney|||Cassandra Abueg|||David A Brown|||Ewa Czyz|||Michal Tendera|||Andras Janosi|||Robert P Giugliano|||Robert A Kloner|||W Douglas Weaver|||Christoph Bode|||Jacek Godlewski|||Bela Merkely|||C Michael Gibson

Journal: American heart journal

Publication Type: Journal Article

Date: 2013

DOI: 10.1016/j.ahj.2012.12.008

ID: 23537966

Affiliations:

Affiliations

    PERFUSE Study Group, Department of Medicine, Cardiovascular Division, Beth Israel Deaconess Medical, Harvard Medical School, Boston, MA 02215, USA.|||||||||||||||||||||||||||||||||||||||

Abstract

Although significant efforts have been made to improve ST-segment elevation myocardial infarction (STEMI) outcomes by reducing symptom-onset-to-reperfusion times, strategies to decrease the clinical impact of ischemic reperfusion injury have demonstrated limited success. Bendavia, an intravenously administered mitochondrial targeting peptide, has been shown to reduce myocardial infarct size and attenuate coronary no-reflow in experimental modelswhen given before reperfusion.

Chemical List

    Oligopeptides|||arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide